Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The FDA classified LifeVac as a Class II medical device
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
Giredestrant shows promise despite missing primary goal
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Subscribe To Our Newsletter & Stay Updated
